Friday 5 December 2014
FDA approves ruxolitinib to treat patients with polycythemia vera
The USA Food and Drug Administration (FDA) approved on 4 December 2014 a new use for ruxolitinib (Jakafi) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Ruxolitinib is the first drug approved by the FDA for this condition. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment